1120 / 1851
Rationale for integrating Sunitinib
and PCI in ED-SCLC
The potential for synergy between PCI and sunitinib is supported by both preclinical
and clinical reports.
It has previously been established that
small cell lung cancer expresses
vascular
endothelial growth factor (
VEGF
)
receptors
and that
VEGF is required
for the
development of
brain metastases
.
In
murine models
, the delivery of
antiangiogenic agents
alone to the brain has
been shown to
slow the growth of brain metastases
. Sunitinib seems to have a
“single-agent activity” against brain metastases also in human models.